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Abstract
Vanadium compounds have been shown to cause a variety of biological and metabolic effects including inhibition of certain
enzymes, alteration of contractile function, and as an insulin like regulator of glucose metabolism. However, the influence of
vanadium on metabolic and ionic changes in hearts remains to be understood. In this study we have examined the influence of
vanadate on glucose metabolism and sodium transport in isolated perfused rat hearts. Hearts were perfused with 10 mM glu-
cose and varying vanadate concentrations (0.7–100 µM) while changes in high energy phosphates (ATP and phosphocreatine
(PCr)), intracellular pH, and intracellular sodium were monitored using 31P and 23Na NMR spectroscopy. Tissue lactate, glyco-
gen, and (Na+, K+)-ATPase activity were also measured using biochemical assays. Under baseline conditions, vanadate increased
tissue glycogen levels two fold and reduced (Na+, K+)-ATPase activity. Significant decreases in ATP and PCr were observed in
the presence of vanadate, with little change in intracellular pH. These changes under baseline conditions were less severe when
the hearts were perfused with glucose, palmitate and β-hydroxybutyrate. During ischemia vanadate did not limit the rise in
intracellular sodium, but slowed sodium recovery on reperfusion. The presence of vanadate during ischemia resulted in at-
tenuation of acidosis, and reduced lactate accumulation. Reperfusion in the presence of vanadate resulted in a slower ATP
recovery, while intracellular pH and PCr recovery was not affected. These results indicate that vanadate alters glucose utiliza-
tion and (Na+, K+)-ATPase activity and thereby influences the response of the myocardium to an ischemic insult. (Mol Cell
Biochem 170: 53–64, 1997)
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Introduction
Interest in the biological importance of vanadium compounds
and of their role in human metabolism has recently increased
due to their potential usefulness in the management of dia-
betes [1]. Early studies have demonstrated that vanadium is
essential in ensuring normal growth in chicks and rats [2–5].
Vanadate (+ 5 oxidation state) and/or vanadyl (+ 4 oxidation
state) ions have been shown to inhibit (Na+, K+)-ATPase in
vitro [6, 7], influence the activities of various enzymes [2,4]
and exert a number of insulomimetic actions in a variety of
cell types [8]. Studies, in vitro, have demonstrated a multi-
tude of metabolic effects by vanadium compounds [9], such
as (a) enhanced glucose uptake and oxidation in adipocytes
[10–12], (b) increased glycogen synthesis in adipocytes and
liver [9, 13, 14], and (c) inhibition of glycolysis in certain cell
types [15]. In muscle, vanadium and insulin produce quali-
tatively similar changes in glucose metabolism, but the mag-
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nitude of these may differ depending on the metabolic path-
way [1, 16]. Inhibition of hepatic cholesterol and phospholi-
pid synthesis by vanadium compounds have also been
reported [17, 18]. The mechanism of the insulin like action
of vanadium compounds in vivo is still being investigated in
detail [14], much attention being focussed on its effects on
carbohydrate metabolism [19–21]. Recent studies have dem-
onstrated that oral administration of vanadium compounds
normalizes blood glucose levels, cardiac performance, and
fluid intake in diabetic rats [1, 22–24]. The in vitro and ani-
mal studies have been recently followed by clinical studies
of administration of small doses of vanadyl sulphate or so-
dium metavanadate to diabetic patients for short periods of
time. Although these doses are about 100-fold lower than
those used in most animal studies, beneficial effects were
observed [25, 26].
Vanadate has been shown to exert a positive inotropic ef-
fect on the cardiac muscle of some animal species [27–29],
whereas in other species, a negative inotropic effect is observed
at lower concentrations [28, 29]. Although vanadate inhibits
cardiac (Na+, K+)-ATPase [4, 30] and stimulates adenylyl cy-
clase increasing tissue cyclic AMP [28, 31], its inotropic ef-
fect does not appear to involve either of these mechanisms [28,
29, 32]. The influence of vanadate on myocardial Ca2+ trans-
port has been suggested to be due to the inhibition of sarco-
lemmal (SL) and sarcoplasmic reticular (SR) Ca2+-stimulated
ATPase activity by vanadate [33–36]. Insulin-like effects of
vanadate on the myocardium [14, 19, 37] appear to proceed
by mechanisms different from those of insulin [38].
Since the above actions of vanadate can profoundly influ-
ence high energy phosphate metabolism, sodium and calcium
homeostasis, we hypothesized that vanadate perfusion would
increase glycogen synthesis, inhibit glycolysis as well as the
(Na+, K+)-ATPase activity, and influence the metabolic and
ionic changes during ischemia and reperfusion. Therefore,
we measured changes in high energy phosphates and intrac-
ellular pH by 31P NMR and intracellular sodium by 23Na NMR
using TmDOTP5– as a shift agent [39–41]. These NMR results
were complemented by biochemical assays on the effect of
vanadate on heart glycogen, lactate and (Na+, K+)-ATPase
activity under normal and ischemic conditions. Simultane-
ous observation of all the vanadate effects on the perfused
rat heart model allowed further understanding of the molecu-
lar mechanisms of its action.
Materials and methods
All experiments were performed with the approval of the
Animal Use and Care Committee for Research at the Uni-
versity of Texas at Dallas and the University of California,
Davis.
Materials
All chemicals and biochemicals were obtained from Sigma
Chem. Co., unless stated otherwise. The macrocyclic ligand
1, 4, 7, 10-tetraazacyclododecane -N, N′, N″, N′″-tetra
(methyenephosphonate) (DOTP8–) and its thulium (III) com-
plex (TmDOTP5–) were synthesized and characterized as de-
scribed elsewhere [39–41]. Male Sprague-Dawley rats
(250–300 g) with free access to food and water were anesthe-
tized with ether and injected in the femoral vein with 200 IU
heparin before excision of the heart, which was then placed
in 4°C perfusion medium. The aorta was immediately can-
nulated and the heart was perfused in the Langendorff mode
at a perfusion pressure of 70 cm H2O [40]. A latex balloon
was placed in the left ventricle. Developed pressure and spon-
taneous heart rate were monitored using a fluid-filled cath-
eter and recorded on a Coulbourne strip chart recorder. The
heart was placed in an 18 mm o.d. NMR tube and perfused
as described elsewhere [40]. The recirculating perfusate was
a phosphate-free Krebs-Henseleit (K-H) solution containing
(in mM) 143 Na+, 130.8 Cl–, 25 HCO3–, 5.0 K+, 3.9 Ca2+, 1.2
Mg2+, 1.2 SO4
2–
, 3.5 TmDOTP5– and 10 glucose continuously
bubbled with a mixture of 95% O2 and 5% CO2. Small
aliquots of a 50 mM ammonium metavanadate (from Aldrich
Chem. Co.) aqueous solution were added to the perfusate in
order to obtain the desired final concentration of vanadate.
NMR spectroscopy
23Na and 31P NMR spectra were obtained on a General Elec-
tric GN 500 (11.75 T) spectrometer operating at 132.28 MHz
for 23Na and at 202.415 MHz for 31P, equipped with an 18 mm
probe tunable to 23Na or 31P, using conditions described else-
where [40]. Magnetic field homogeneity was adjusted using
the 23Na free induction decay; a linewidth of 24–26 Hz on
the extracellular 23Na resonance was usually obtained in the
presence of 3.5 mM TmDOTP5– in the perfusate. 23Na spec-
tra were acquired using a ± 1600 Hz spectral width, 2048 data
points, a 90°pulse, 184 acquisitions and a 0.33 sec interpulse
delay over a period of 1 min. Control 31P spectra before and
after the addition of TmDOTP5– and serial 31P spectra after
the addition of vanadate were acquired over a ± 4000 Hz spec-
tral width using 4096 data points in 4 min. with a 40° pulse,
200 acquisitions and a 1.2 sec interpulse delay. For the
ischemia and recovery experiments, 31P and 23Na NMR meas-
urements were made on control hearts (n = 3) and 40 µM
vanadate treated hearts (n = 3) in the presence of 3.5 mM
TmDOTP5– and [Ca2+]
t
 = 3.9 mM during ischemia periods of
12 min (31P experiments) or 10 min (23Na experiments) and
during recovery for 15 min (31P experiments) or 10 min (23Na
experiments). The NMR spectra were collected every 3 min
(31P spectra) or every minute (23Na spectra). 23Na and 31P spec-
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tra were processed with a combined exponential and Gaussian
function of 6 Hz and 40 Hz, respectively [40].
23Na NMR spectra were analysed using the least-squares
fitting algorithm supplied in the General Electric software,
which allowed the calculation of linewidth, peak height, area
and chemical shift for each spectrum [40]. Intracellular Na+
concentrations were calculated from peak areas as previously
described [40]. Intracellular pH values were obtained in the
usual manner from the chemical shift of the Pi resonance in
the 31P NMR spectra [40]. Intracellular Na+ concentrations
and pH are reported as means. Standard deviations (SD) are
very similar to those obtained in previous studies [40]. In
particular, SD values for all pH determinations were lower
than 0.012.
Lactate measurements
Hearts were freeze-clamped at different time points (prior to
ischemia, end of ischemia, and end of reperfusion, n = 7
hearts per time point, see conditions of the NMR experi-
ments) and the lactate extracted with 6% perchloric acid. The
perchloric acid extracts were then neutralized with KOH and
the lactate measured using standard biochemical assays [42].
Glycogen measurements
Glycogen content prior to ischemia was measured in freeze-
clamped hearts. Following perfusion with or without vanad-
ate the hearts were rapidly freeze-clamped using aluminium
tongs and assayed for glycogen [43]. Glycogen content is
expressed as µmol glucose equivalents per gram dry weight
(µmol glu/gdw).
Measurements of (Na+, K+)-ATPase activity
Ouabain sensitive (Na+, K+)-ATPase activity was measured
in homogenates of hearts (n = 6) and expressed as µM ADP
formed/min/mg total protein [44]. Heart tissue was homog-
enized at 4°C in 2 ml of 0.2 M sucrose-0.02 M Tris-HCl
buffer (pH 7.5) containing 100 µl of 57 mM phenylmethyl-
sulfonyl fluoride and 10 µl of 1 mg/ml leupeptide as protease
inhibitor, with a polytron homogenizer for four periods, each
period not exceeding 15 sec, and then centrifuged at 100 g
for 10 min at 4°C. The reaction was started by the addition
of 20 µl of supernatant to a 1 ml × 1 cm cuvette containing
final concentrations of 100 mM NaCl, 10 mM KCl, 2.5 mM
MgCl2, 2 mM EGTA, 1 mM Tris-ATP, 1 mM phosphoe-
nolpyruvate, 30 mM imidazole-HCI buffer at pH 7.4, 0.15
mM NADH, 50 µg lactate dehydrogenase, 30 µg pyruvate
kinase with or without ouabain. After a 30 min stabilization
period, the linear rate of oxidation of NADH was monitored
at 340 nm. ATPase activity was calculated from the linear
portion of the curve using the mM extinction coefficient of
NADH, volume of the reaction mixture, and the amount of
heart homogenate, as shown below:
ATPase activity = {slope(OD units/min)/6.22(OD units.ml/
µmol)} × {1 ml/protein in mg}
The protein concentrations were assayed in each freeze-
clamped heart.
Protocols
NMR experiments and biochemical assays were performed
in which some hearts were subjected to baseline perfusion
with vanadate while other hearts were subjected to ischemia
and reperfusion in the presence of vanadate.
Group I: perfusion with vanadate under baseline
conditions
Glucose as a substrate
Hearts (n = 3) were subjected to 20 min of perfusion in nor-
mal Krebs-Hensleit buffer (10 mM glucose as the sole
substrate) followed by increasing concentrations of vanad-
ate (from 0.7–100 mM at least 10 min at each concentration).
In the cases of 40 mM and 100 mM concentrations the hearts
were exposed for a longer period to determine the extent of
metabolite and functional deterioration with time.
Mixed substrate
Hearts (n = 3) were subjected to 20 min of perfusion in Krebs-
Hensleit buffer containing 10 mM glucose, 1 mM palmitate,
and 0.25 mM β-hydroxybutyrate followed by increasing con-
centrations of vanadate (from 20–40 µM) to determine the
extent of metabolite and functional deterioration with time.
Group II: presence of vanadate during ischemia and
reperfusion
Set A
Six hearts were perfused with vanadate-free buffer then sub-
jected to global ischemia followed by reperfusion in the same
buffer.
Set B
Six hearts were perfused with 40 mM vanadate prior to
ischemia, then subjected to global ischemia followed by
reperfusion with 40 mM vanadate.
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Set C
Six hearts were perfused with 40 mM vanadate prior to
ischemia, then subjected to global ischemia followed by
reperfusion in vanadate-free perfusate.
In the 23Na NMR experiments the duration of global
ischemia was 10 min followed by 10 min of reperfusion,
while in 31P NMR experiments duration of global ischemia
was 12 min followed by 15 min of reperfusion.
Statistical analysis
Results are given as the mean ± SD for the indicated number
of rat hearts. Comparisons among control and vanadate-
treated hearts were carried out by comparing means using
Student t test. Differences were considered statistically sig-
nificant at p < 0.05.
Results and discussion
Effect of vanadate on heart developed pressure
The left ventricular pressure (LVDP) decreased as function
of perfusate vanadate concentration. The initial positive ino-
tropic response observed with 1 µM vanadate diminished as
the vanadate concentration was increased to 10 µM. At vana-
date concentrations of 10 µM and higher, a negative inotropic
response was observed. The percent reduction in LVDP upon
treatment with 10, 20, 40 µM vanadate concentrations for 10
min was 44 ± 6%, 59 ± 7%, and 63 ± 5%, respectively. Con-
tinuous perfusion with 40 µM vanadate for 26 min or more
resulted in complete loss of LVDP and heart rhythm. Wash-
out of vanadate with normal Krebs-Hensleit buffer resulted
in a marginal recovery of LVDP function (27 ± 6%) and heart
rhythm. These results were consistent with the effects of
vanadate on contractile function as reported in the literature
[2, 27–29, 32, 35, 36]. In particular, it has been shown that
the inotropic effect of 10 mM vanadate is highly dependent
on the Ca2+ content of the medium (eg 10 mM vanadate
causes a LVDP increase of 459% at 0.3 mM Ca2+ but a de-
crease to 66% at 2.0–3.0 mM Ca2+ [36]).
Effect of vanadate under baseline conditions
High energy phosphates and intracellular pH
Serial 31P NMR spectra (recorded every 4 min) obtained
before and after successive additions of vanadate to the
perfusion medium are shown in Figs 1A–C. As the vanadate
concentration was increased, the 31P NMR resonance intensi-
ties of phosphocreatine (PCr), β-ATP, and inorganic phos-
phate (Pi) changed dramatically (see Table 1). The succes-
sive reductions in PCr and ATP paralleled the increase in Pi.
Perfusion with 40 µM vanadate for 26 min resulted in reduc-
tion of PCr by about 87% (compared to baseline) and of ATP
by 91%.
The changes in Pi were quite dramatic with increases of
5–6 times baseline control values during perfusion with 40
µM vanadate. The Pi chemical shift, however, was unchanged
with vanadate, indicating that the intracellular pH had not
changed. Therefore, under baseline perfused conditions we
were unable to detect any marginal changes of pH due to
vanadate, as the intracellular proton generating metabolites
are constantly washed out in those conditions.
The observation of a broadening of the 31P NMR resonances
Fig. 1. Time evolution of the 31P NMR signals (A, B, C) of a perfused rat
heart, in the presence of increasing concentrations of vanadate and after its
removal from the perfusion medium: (A) ATP Pβ signal; (B) PCr signal;
(C) Pi signal.
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of ATP and Pi, but not of PCr, after exposure to extracellular
vanadate and even after removal of vanadate by washing (Fig.
1), indicated that the intracellular monovanadate was at least
partially reduced to the paramagnetic vanadyl species, VO2+
[45–49]. This species is known to bind preferentially to the
phosphate groups of intracellular ATP and Pi, resulting in a
broadening of their 31P NMR signals [50].
In general, under normoxic conditions ATP is generated
mostly via oxidative phosphorylation while during ischemic
conditions ATP is generated principally via glycolysis. The
phosphomonoester (PME) resonance in the 31P NMR spec-
trum is a good indicator of phosphorylated compounds, spe-
cifically the intermediates of glycolysis. Under baseline
conditions we observed small changes in PME resonance in
the presence of vanadate when glucose was used as the
substrate. The PME resonance was significantly greater in 40
µM vanadate perfused hearts (Table 1) compared to the un-
treated control hearts. Despite statistical significance in PME
values with 40 µM vanadate perfusion, the changes in PME
do not correlate with changes in ATP and PCr. In addition,
when the hearts were perfused with mixed substrates (fatty
acids, glucose, and ketone bodies), presence of 40 µM vana-
date did not increase PME levels. The presence of 40 µM
vanadate reduced ATP and PCr levels by a greater amount
in glucose perfused hearts compared to mixed substrate
perfused hearts. These observations suggest that the vanad-
ate induced reduction in baseline ATP and PCr levels may
be multifactorial. Under baseline conditions, based on PME
levels, it is reasonable to conclude that inhibition of glyco-
lysis is a minor component that accounts for the observed
vanadate induced reduction in ATP. Therefore it is likely that
vanadate may influence the ATP generating enzymes in the
TCA cycle and/or influence ATP utilization.
The vanadate induced changes in ATP, PCr, and Pi were
less dramatic in hearts perfused with a mixed substrate con-
taining palmitate, glucose, and β-hydroxybutyrate compared
with glucose perfused vanadate hearts. However, the vanad-
ate induced reductions in phosphorylated metabolites, in the
presence of mixed substrates, were still significantly greater
than in untreated control hearts (p = 0.003). These data sug-
gest that under baseline conditions vanadate influences high
energy phosphate levels either by influencing their produc-
tion (inhibiting ATP generating steps in oxidative phospho-
rylation) and/or utilization.
Glycogen
Perfusion with 40 µM vanadate significantly increased gly-
cogen levels in hearts from 37.2 ± 3 µmol glu/gdw (n = 6) to
72.6 ± 11 µmol glu/gdw (n = 6). The magnitude of increase
observed with vanadate perfusion was similar to that ob-
served for hearts perfused with high levels of insulin (69.3 ±
7 µmol glu/gdw, n = 6, with 50 units liter–1 insulin). The pre-
cise mechanism by which vanadate increases glycogen is
unclear. Recent studies by Liu and McNeill [51] demon-
strated that vanadyl sulphate increased cAMP levels and re-
duced glycogen phosphorylase activity in diabetic hearts.
Similar studies on the effect of vanadate on glycogen syn-
thase, glycogen phosphorylase, and cAMP [28, 31] will help
to understand the precise mechanism by which vanadate in-
creases glycogen levels in perfused rat hearts.
(Na+, K+)-ATPase activity
Significant inhibition of (Na+, K+)-ATPase activity was ob-
served at 40 µM and even at much lower concentrations of
vanadate (0.7 µM) (see Table 2), in agreement with recent
studies [36]. The activity of (Na+, K+)-ATPase can be low-
ered by direct inhibition or by lowering the availability of
glycolytically produced ATP. Since vanadate can directly
inhibit (Na+, K+)-ATPase as well as glycolysis, the magnitude
of (Na+, K+)-ATPase inhibition is likely due to a cumulative
effect of the above two mechanisms.
Intracellular sodium
In another series of experiments, the effect of vanadate addi-
tion on the intra- and extracellular sodium in hearts was inves-
tigated using 23Na NMR spectroscopy. 3.5 mM TmDOTP5–
was added to the perfusate together with excess (3.9 mM)
Ca2+ to maintain free, ionized Ca2+, [Ca2+]f, near 1.0 mM [39,
40]. 23Na NMR spectra of hearts were collected before and
Table 1. Changes in phosphocreatine (PCr), ATP, inorganic phosphate (Pi),
and phosphomonoester (PME) expressed as a fraction of baseline, of
perfused rat hearts under baseline conditions (n = 3), obtained by 31P NMR,
as a function of vanadate perfusion time
Hearts Glucose substrate Mixed substrate
Time of exposure (min) Time of
exposure (min)
5 10 25 25
PCr
control 1.00 0.99 ± 0.02 0.97 ± 0.03 0.99 ± 0.03
vanadate (20 µM) 0.82 ± 0.06 0.78 ± 0.04 nd 0.88 ± 0.04
vanadate (40 µM) 0.67 ± 0.04 0.62 ± 0.06 0.13 ± 0.02 0.66 ± 0.12
β-ATP
control 1.00 0.98 ± 0.03 0.98 ± 0.05 0.98 ± 0.02
vanadate (20 µM) 0.95 ± 0.03 0.82 ± 0.02 nd 0.92 ± 0.03
vanadate (40 µM) 0.77 ± 0.02 0.63 ± 0.04 0.09 ± 0.03 0.56 ± 0.09
Pi
control 1.00 1.04 ± 0.03 1.02 ± 0.04 1.08 ± 0.02
vanadate (20 µM) 1.09 ± 0.04 1.27 ± 0.06 nd 1.42 ± 0.07
vanadate (40 µM) 1.82 ± 0.06 2.18 ± 0.09 2.55 ± 0.12 1.82 ± 0.12
PME
control 1.00 1.16 ± 0.03 1.09 ± 0.02 1.02 ± 0.03
vanadate (20 µM) 1.06 ± 0.03 1.12 ± 0.04 1.32 ± 0.12 1.16 ± 0.07
vanadate (40 µM) 1.14 ± 0.08 1.36 ± 0.07 1.72 ± 0.18 1.28 ± 0.11
nd – Not determined. Values are the mean ± SD (n = 3 hearts in each group).
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after addition of vanadate to the perfusion medium, in con-
centrations of 1, 10 and 40 µM. 31P NMR spectra (conditions
similar to that of 23Na NMR experiments) during addition of
vanadate, in the presence of TmDOTP5–, showed no major
alteration in intracellular pH or the intensities of the usual
phosphorylated compounds. Despite the inhibition of (Na+,
K+)-ATPase activity, no change in intracellular sodium con-
centration was observed in the presence of vanadate. The lack
of changes in intracellular sodium could be due to the low
visibility of intracellular sodium by NMR. It has been sug-
gested that only about 40% of intracellular sodium is visible
by NMR [39, 40]. To address this issue of sodium changes,
we performed experiments measuring changes in intracellu-
lar sodium on freeze-clamped heart extracts using atomic
absorption spectroscopy [39, 40]. This invasive technique is
sensitive to changes in sodium, even in the nanomolar range,
under baseline conditions. These experiments revealed that
intracellular sodium was significantly higher in 40 µM vana-
date perfused hearts compared to the controls (intracellular
sodium being 41.2 ± 6.3 mM in vanadate hearts versus 24.6
± 3.9 mM in controls, n = 6 in each group, p = 0.03).
Effect of vanadate during ischemia and reperfusion
LVDP before and after ischemia
The LVDP was 112.6 ± 9.2 cm of H2O pressure in controls
while it was 48 ± 5.4 cm of H2O pressure in 40 µM vanadate
perfused hearts prior to the start of global ischemia. On
reperfusion, the LVDP recovery was 65.8 ± 11.4 cm of H2O
pressure in controls, 58.6 ± 14.2 cm of H2O pressure in set B
hearts (vanadate not present during reperfusion), and 78.9 ±
16.5 cm of H2O pressure in set C hearts (vanadate present
during reperfusion).
Lactate and intracellular pH
Levels of lactate were similar in control and vanadate hearts
prior to ischemia. However, during ischemia and reperfusion,
hearts exposed to vanadate had significantly reduced levels
of lactate compared to the control hearts (Table 3). This dem-
onstrated that glycolysis was inhibited by vanadate. The de-
gree of intracellular acidification during ischemia (Fig. 2), as
expected, was concordant with biochemical measurements of
lactate release in the two groups. Intracellular pH was identi-
cal in the two groups immediately prior to global ischemia.
During the first 5 min of global ischemia, the fall in pH was
rapid in both control and vanadate hearts. After the first 5 min,
the fall in pH continued in control hearts, but was blunted in
vanadate hearts, resulting in significantly different end-
ischemic pH values of 5.88 ± 0.12 and 6.46 ± 0.09 in control
and vanadate hearts. Similar observations of reduced acidosis
during global ischemia have been reported in glycolysis inhib-
ited substrate-free pyruvate perfused hearts [52]. Upon
reperfusion, both groups of hearts had similar rates of pH re-
covery. These observations show that the pH recovery mecha-
nisms, such as the Na+-H+ exchanger, the Cl–HCO3
–
 transporter,
the lactate-H+ cotransporter, are unaffected by vanadate.
Proton and lactate accumulation during ischemia may pri-
marily be detrimental to the cardiocyte. Reperfusion after
moderate periods of global ischemia can result in additional
injury. Evidence in the literature suggests that the following
sequence of events leads to irreversible myocyte injury: (a)
proton production results in intracellular sodium accumulation
(via the Na+-H+ exchanger) and (b) increases in sodium lead
to calcium accumulation (via the Na+-Ca2+ exchanger) [53].
However, recent findings have demonstrated that the mecha-
nisms can operate whereby the intracellular sodium accumu-
lation can be attenuated without limiting acidosis [54, 55].
Among the multiple potential sources of hydrogen ions in
ischemic tissue [52], it has been shown that the hydrolysis
of ATP is the main proton producing process during total
global ischemia in the perfused rat heart [56, 57]. The levels
of ATP are determined by the extent of glycogenolysis and
glycolysis [56, 57]. Thus, the reduced acidosis observed
during ischemia in the presence of vanadate correlates well
with reduced glycogenolysis and glycolysis in the ischemic
heart in the presence of vanadate.
High energy phosphates
Figures 3A and 3B demonstrate the changes in high energy
phosphates observed in these three groups of hearts during
ischemia and reperfusion. Vanadate exposure significantly
lowered phosphocreatine (PCr) levels prior to initiation of
Table 2. Effect of vanadate on rat heart (Na+, K+)-ATPase activity measured
in heart homogenates after perfusion under baseline conditions
Hearts (Na+, K+)-ATPase activity
(µmol/hour.mg total protein)
Control hearts 5.12 ± 0.06
Vanadate hearts 2.58 ± 0.03**
(40 µM)
Vanadate hearts 3.12 ± 0.04**
(0.7 µM)
**Significantly lower than in control hearts (p = 0.005). Values are the
mean ± SD (n = 6 hearts in each group).
Table 3. Effect of vanadate on rat heart lactate measured in freeze-clamped
heart extracts after perfusion under baseline, ischemic and reperfusion
conditions
Hearts Lactate (µmol/g dry weight)
Start End ischemia End reperfusion
Control 3.2 ± 0.2 176 ± 19 18.9 ± 2.7
Vanadate 2.2 ± 0.9 122 ± 11* 9 ± 1.2**
(40 µM)
*,**Denotes significant differences between control and vanadate treated
hearts, p < 0.05. Values are the mean ± SD (n = 7 in each group).
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global ischemia. PCr fell rapidly in the control group, while
in vanadate hearts the loss of PCr was slower with complete
depletion of PCr in all groups after the first five minutes of
global ischemia. Reperfusion caused a rapid but partial re-
turn of PCr in all groups within 5 min.
Prior to global ischemia, the ATP levels were significantly
reduced (p < 0.05) in vanadate hearts compared to the con-
trol hearts. During the first 5 min of ischemia, the level of
ATP was maintained in both control and vanadate hearts. All
hearts had negligible amounts of ATP remaining by 12 min
of ischemia. From this data, it is not possible to distinguish
the source of ATP (ie ATP from glycolysis or glycogenoly-
sis) that contributes to proton production during ischemia.
In both the control and group B hearts (vanadate during
ischemia alone, not upon reperfusion) ATP recovery was
similar, with approximately 40% ATP recovery on reper-
fusion. When vanadate was present during reperfusion (set
C hearts), the ATP recovery was significantly reduced rela-
tive to control hearts. This reduction in ATP recovery is likely
due to the effect of vanadate on ATP production (via oxidative
phosphorylation and glycolysis) and/or ATP utilization.
PME
It has been demonstrated by Schaefer et al. [52] that the end-
ischemic PME/Pi ratio can reveal qualitative information on
glycolysis during global ischemia. The end-ischemic PME/
Pi ratios were higher in 40 µM vanadate perfused hearts com-
pared to the controls (PME/Pi ratios were 0.41 ± 0.06 in vana-
date hearts compared to 0.26 ± 0.03 in controls). It is well
established that anaerobic glycolysis is the dominant meta-
bolic pathway during global ischemia in perfused hearts [52,
54–57]. The lactate and PME/Pi data shown here suggest that
vanadate inhibits glycolysis during global ischemia.
Intracellular sodium
Figure 4 shows the effect of vanadate on the time evolution
of the intracellular sodium signal, [Na+]i, during global (10
min) ischemia and reperfusion. The presence of 40 µM vana-
date in the perfusion medium did not prevent an increase in
[Na+]i during ischemia. During reperfusion, the presence of
vanadate significantly slowed the return of intracellular Na+
back toward preischemic levels. Studies have demonstrated
that the recovery of intracellular sodium during reperfusion,
is in part, dependent on the (Na+, K+)-ATPase activity [53,
54]. The slow recovery of intracellular sodium on reper-
fusion, observed in vanadate treated hearts, is suggestive of
the inhibition of (Na+, K+)-ATPase by vanadate, consistent
with our observation under baseline conditions. This is
consistent with the observations described above of the ef-
fects of vanadate on the (Na+, K+)-ATPase activity of perfused
hearts under baseline conditions.
Reduced levels of ATP have been demonstrated to influ-
ence the ion regulatory mechanisms such as the (Na+, K+)-
ATPase, Ca2+-ATPase, and the ATP sensitive K+ channels [57,
58]. Therefore, the retarded intracellular Na+ recovery in
vanadate hearts is consistent with the reduced levels of ATP.
Despite the limitation of acidosis, the slower intracellular Na+
recovery due to inhibition of the (Na+, K+)-ATPase activity
may offset the beneficial effects of reduced proton load dur-
ing global ischemia in vanadate hearts.
Fig. 2. Changes in intracellular pH, measured by 31P NMR, of a perfused rat heart, during global ischemia and reperfusion. The symbols open squares and
open circles represent control and 40 µM vanadate treated hearts, respectively. *Denotes that pH is significantly different from the control hearts (p < 0.05).




The findings in this study should be interpreted within the
limitations of the experimental design. First, the influence of
vanadate on metabolites and ions, in the presence of physi-
ological substrates (such as fatty acids, ketone bodies, etc.),
would likely be less drastic than that obtained in this study
Fig. 3. Changes in PCr (3A) and ATP (3B), measured by 31P NMR, of a perfused rat heart, during global ischemia and reperfusion. The control hearts are
represented by open circles, the hearts treated with 40 µM vanadate only during ischemia are represented by open squares (set B), and the hearts treated with
40 µM vanadate during ischemia and reperfusion (set C) are represented by open diamonds. At the time of –6 min hearts were exposed to vanadate (vanadate
hearts only), at the time of 0 ischemia was initiated, and at the end of 12 min reperfusion was started. ATP was significantly (p < 0.05) different during
reperfusion in the set C hearts.
with glucose as the only substrate. Second, the use of 23Na
NMR to measure intracellular sodium is restricted by the
visibility of the intracellular sodium resonance. Typically, the
visibility of intracellular sodium is about 40%. Therefore,
despite lower activity of (Na+, K+)-ATPase, it was not possi-
ble to observe increases in intracellular sodium by NMR.
However, independent intracellular sodium measurements
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